TABLE 3.

Pharmacokinetic data from clinical trials of UA-loading nanoparticles.

Parameter	Lipo A	Lipo B			Lipo C
Administration Route	Intravenous	Intravenous			Intravenous
Dose (mg/m2)	74 (double dose)	37	74	98	37	74 (single dose)	98	74 (double dose)
${\text{t}}_{1/2}$ T1/2(hours)	4.58 ± 2.04	4.59 ± 2.44	4.46 ± 1.41	3.90 ± 2.08	4.59 ± 2.44	4.46 ± 1.41	3.90 ± 2.08	4.58 ± 2.04
${\text{V}}_{\text{d}}$ (L/m2)	NA	NA	NA	NA	58.7 ± 33.0	64.3 ± 17.9	55.4 ± 28.1	88.6 ± 31.8
CL (L/h/m2)	NA	8.65 ± 1.09	10.2 ± 1.46	9.94 ± 1.13	8.67 ± 1.07	10.20 ± 1.46	9.94 ± 1.13	14.40 ± 3.94
${\text{AUC}}_{0-\text{t}}$ (ng⋅h/mL)<	5,172 ± 1,136	4,213 ± 606	7,175 ± 999	9,696 ± 1,134	4,203 ± 588	7,175 ± 999	9,696 ± 1,134	5,172 ± 1,136
${\text{AUC}}_{0-\infty }$ (ng⋅h/mL)	5,498 ± 1,525	4,339 ± 574	7,418 ± 1,057	9,971 ± 1,144	4,329 ± 556	7,418 ± 1,057	9,971 ± 1,144	5,498 ± 1,525
${\text{MRT}}_{0-\text{t}}$ (hour)	NA	3.69 ± 0.36	3.93 ± 0.37	3.84 ± 0.34	3.69 ± 0.36	3.93 ± 0.37	3.84 ± 0.34	3.34 ± 0.55
${\text{MRT}}_{0-\infty }$ (hour)	NA	4.28 ± 0.91	4.56 ± 0.88	4.41 ± 0.95	4.29 ± 0.90	4.56 ± 0.88	4.41 ± 0.95	4.31 ± 1.89
${\text{C}}_{\text{max}}$ (ng/ml)	1,589 ± 635	1835 ± 438	2,865 ± 868	3,457 ± 856	1835 ± 438	2,865 ± 868	3,457 ± 856	1,589 ± 635
${\text{T}}_{\text{max}}$ (hour)	NA	4.03 ± 0.04	4.02 ± 0.04	4.0 ± 0.00	4.03 ± 0.04	4.02 ± 0.04	4.00 ± 0.00	3.00 ± 1.41

Notes: ${\text{t}}_{1/2}$ , half-life time; ${\text{V}}_{\text{d}}$ , distribution volume; CL, clearance; AUC, area under curve of concentration vs time; MRT, mean retention time; ${\text{C}}_{\text{max}}$ , maximum plasma concentration; ${\text{T}}_{\text{max}}$ , time required to reach maximum plasma concentration.